Keyphrases
Adverse Events Profile
20%
Confidence Interval
60%
Curative Treatment
20%
Cutaneous Squamous Cell Carcinoma (cSCC)
100%
Disease Progression
20%
Duration of Response
20%
Epidermal Growth Factor Receptor
20%
Epidermal Growth Factor Receptor Inhibitors
20%
Gefitinib
100%
Interest Rates
20%
Metastatic Cutaneous Squamous Cell Carcinoma
20%
Oncogenesis
20%
Overall Response Rate
20%
Partial Response
20%
Phase II Clinical Trial
100%
Phase II Study
20%
Preclinical Data
20%
Previous Experience
20%
Progression-free Survival
20%
Recurrent Metastatic
20%
Response Rate
60%
Side Effect Profile
20%
Single Institution
20%
Single-arm Study
20%
Stable Disease
20%
Target Response
40%
Tumor Subtype
20%
Medicine and Dentistry
Adverse Event
20%
Arm
100%
Carcinogenesis
20%
Clinical Trial
100%
Disease
20%
Disease Exacerbation
20%
Epidermal Growth Factor Receptor
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Gefitinib
100%
Neoplasm
20%
Progression Free Survival
20%
Side Effect
20%
Skin Carcinoma
100%